Enter the vial size and the diluent volume to get the solution's strength in mg/mL, as a percentage, and in micrograms per 0.1 mL. Semax's stated primary route is intranasal, so nothing here is measured on a syringe, and Peptigrity states no Semax dose. The compound itself is covered in the Semax guide.
A 10 mg vial of Semax reconstituted with 10 mL gives 10 ÷ 10 = 1 mg/mL (0.1%) — 1 mg/mL × 0.1 mL = 100 mcg in every 0.1 mL. The 10 mL is derived from the 0.1% strength in the site's intranasal guide, not a standard volume, and there is no per-spray figure here because no source states a spray volume.
10 mL is a derived display default — the volume that puts a 10 mg vial at 0.1%, the Semax strength in Peptigrity's intranasal guide — not a standard volume. No page on the site states how much one spray delivers, so the per-spray tile stays blank until you enter your own pump's volume.
Semax has 300 independent lab tests on file at Peptigrity, averaging 99.45% HPLC purity across the tests that report one. Purity is not net content: a clean certificate confirms what is in a vial, not how much. See the Semax lab-test records.
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from a fragment of adrenocorticotropic hormone, ACTH(4-10), approved in Russia as a nootropic and neuroprotective agent. It is a peptide — but it is not an injectable-route compound on this platform: the compound page names intranasal as the primary clinical route, and describes that route as allowing direct nose-to-brain delivery. The table below is what the compound page states, as last updated in August 2026.
| Question | What the compound page states | Evidence level |
|---|---|---|
| What is it? | A synthetic heptapeptide derived from ACTH(4-10), with N-terminal modifications for stability and intranasal bioavailability | Chemical identity |
| Which route? | “Intranasal dosing is the primary clinical route” | Russian clinical use |
| Human evidence? | Approved in Russia for stroke and cognitive disorders; Western Phase 2/3 randomised trials limited | Russian clinical (decades of practice); Western RCT limited |
| A dose? | Peptigrity does not recommend a Semax dose; Russian clinical practice for stroke and cognitive indications varies | None — declined |
| A diluent volume or spray volume? | Neither is stated on the compound page or anywhere else on the site | None |
One Semax-specific caution matters more to a converter than any number in it. N-Acetyl Semax Amidate is Semax with N-terminal acetylation and C-terminal amidation — a different molecule — and the compound page notes that research-grade vendors occasionally sell one labelled as the other. The arithmetic treats the label's milligrams as Semax; only a mass-spectrometry result on a certificate can confirm which molecule the vial holds. The analog has its own page: N-Acetyl Semax Amidate.
There is no dose table because the compound page answers the dose question with a refusal: Peptigrity is an independent review platform, not a medical authority. There is no syringe arithmetic because the route the page names is intranasal, and a nasal solution is described by its strength, not by marks on a U-100 barrel. What can be computed honestly is the strength of the solution you made — and, only if you supply the volume your own pump delivers, the micrograms in one spray.
The one strength with a source on the site is 0.1% (1 mg/mL), listed for Semax in Peptigrity's intranasal peptide guide; the Semax versus Selank comparison records Semax as registered in Russia as 0.1% and 1% nasal drops. Those are strengths of a finished product, not amounts to take, and this page uses them only to anchor the arithmetic.
Strength is vial milligrams divided by total millilitres of solution; percent is mg/mL divided by ten; micrograms in 0.1 mL is mg/mL times 100. The first table gives the total volume that puts each labelled vial size on file at the two registered strengths named on the site — computed on this page from those two percentages, not quoted from anywhere.
| Vial | Volume for 0.1% (1 mg/mL) | Volume for 1% (10 mg/mL) |
|---|---|---|
| 5 mg | 5 mL → 100 mcg per 0.1 mL | 0.5 mL → 1000 mcg per 0.1 mL |
| 10 mg (default) | 10 mL → 100 mcg per 0.1 mL | 1 mL → 1000 mcg per 0.1 mL |
| 20 mg | 20 mL → 100 mcg per 0.1 mL | 2 mL → 1000 mcg per 0.1 mL |
| 30 mg | 30 mL → 100 mcg per 0.1 mL | 3 mL → 1000 mcg per 0.1 mL |
| 50 mg | 50 mL → 100 mcg per 0.1 mL | 5 mL → 1000 mcg per 0.1 mL |
The second table holds the vial at the 10 mg default and varies the diluent, to show how quickly strength moves with volume; every cell is the same division, computed here.
| Diluent, 10 mg vial | mg/mL | Percent | mcg in 0.1 mL |
|---|---|---|---|
| 1 mL | 10 | 1% | 1000 |
| 2 mL | 5 | 0.5% | 500 |
| 5 mL | 2 | 0.2% | 200 |
| 10 mL (default) | 1 | 0.1% | 100 |
A label is not a measurement. The compound page's fact sheet puts the median Semax result at 108% of label across 288 tests that compare measured with labelled quantity (figures as of 21 September 2026). At that median a 10 mg vial holds 10.8 mg, and the same 10 mL gives 1.08 mg/mL — 108 mcg per 0.1 mL rather than 100. Every figure above is computed from the label; your vial's own certificate is the only thing that moves it to the measured figure.
Peptigrity's intranasal guide says that making an intranasal solution from lyophilised powder parallels reconstitution for injection, and that storage follows the same principles as a reconstituted injectable — refrigerated between uses, discarded if the solution turns cloudy or develops sediment. That is generic guidance for peptides, not a Semax-specific finding; the technique itself is in reconstituting peptides step by step.
What no page on the site states for Semax: a diluent, a diluent volume, the container the solution is made up in, a spray volume per actuation, or an in-use period. 10 mL is the total volume the 0.1% arithmetic needs, nothing more. The same guide warns that compounded nasal sprays vary widely in concentration between suppliers, which is one more reason a strength you calculated is only as good as the vial content behind it. For the sister compound with a sourced 0.15% strength, see the Selank calculator.
Per the compound page (Last Updated: August 2026), Semax is approved for medical use in Russia for ischemic stroke recovery, transient ischemic attack and cognitive disorders, but is not approved by the FDA, EMA or other major Western regulators. In April 2026 the FDA removed semax (as semax acetate) from its Category 2 “significant safety risks” bulk-substances list — a change the FDA attributed to the nominations being withdrawn, not a safety clearance, and one that did not authorise compounding. At its July 23–24, 2026 meeting the Pharmacy Compounding Advisory Committee voted 8–5, with one abstention, to recommend semax for the 503A compounding list. The vote is advisory only: pharmacies cannot lawfully compound semax under 503A until the FDA completes rulemaking, which is not expected before late 2027, and the agency may decline. Timeline: FDA peptide regulation 2025–2026.
Independent test records: Semax lab tests. Tracked prices: Semax price per milligram. Country-by-country rules: regulatory status by country.
Peptigrity does not state one. The Semax compound page answers the dose question with a refusal - Peptigrity is an independent review platform, not a medical authority - and says only that Russian clinical practice varies and that intranasal dosing is the primary clinical route. This converter turns a vial and a diluent volume into a strength; it does not supply an amount.
Divide the vial's milligrams by 1 mg/mL: a 10 mg vial needs 10 mL of solution in total, a 5 mg vial 5 mL, a 30 mg vial 30 mL. At 0.1% every 0.1 mL carries 100 mcg. 0.1% is the Semax strength listed in Peptigrity's intranasal guide; no page on the site sets a diluent volume for Semax, so the volume is derived from that strength rather than quoted.
This page cannot say. No page on Peptigrity states how much solution a spray pump delivers per actuation, and pumps differ. Enter the volume your own pump delivers and the calculator multiplies it by the concentration; until then the per-spray figure stays blank.
Because the route the compound page names is intranasal, and a nasal solution is described by its strength - mg/mL, percent and micrograms per 0.1 mL - not by marks on a U-100 syringe.
No. N-Acetyl Semax Amidate is Semax with N-terminal acetylation and C-terminal amidation; they are different molecules, and the compound page notes that some research-grade vendors sell one labelled as the other. The arithmetic here treats the label's milligrams as Semax; only a mass-spectrometry result on a certificate confirms which molecule a vial holds.
Semax is approved for medical use in Russia and is not approved by the FDA, EMA or other major Western regulators. The FDA removed it from its Category 2 bulk-substances list in April 2026 after the nominations were withdrawn, and at its July 23-24, 2026 meeting the Pharmacy Compounding Advisory Committee voted 8-5 to recommend it for the 503A list - an advisory vote, with rulemaking not expected before late 2027.